Want to see OM full AI Analyst Report?
OM Stock Chart & Stats
$4.35
-$0.10(-9.09%)
At close: 4:00 PM EST
$4.35
-$0.10(-9.09%)
Day’s Range― - ―
52-Week Range$3.00 - $21.36
Previous CloseN/A
Volume1.92M
Average Volume (3M)205.25K
Market Cap
$79.99M
Enterprise Value$145.57M
Total Cash (Recent Filing)$156.71M
Total Debt (Recent Filing)$101.61M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Aug 05, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.16
Shares Outstanding18,537,241
10 Day Avg. Volume200,402
30 Day Avg. Volume205,247
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.47
P/FCF Ratio-1.20
Enterprise Value/Market Cap1.82
Enterprise Value/Revenue1.24
Enterprise Value/Gross Profit3.05
Enterprise Value/Ebitda-2.55
Forecast
1Y Price Target
$7.67Price Target Upside76.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$126.77M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Base (~70%)Consumables and service revenue comprising roughly 70% of sales creates an annuity-like stream tied to treatments and installed consoles. This durable pull-through reduces top-line volatility, supports predictable margins and cash flow as installed base scales over quarters and years.
Material Gross Margin ExpansionSustained gross margin improvement and strong product margin indicate meaningful improvement in unit economics. Higher margins reduce required revenue to breakeven, improve cash conversion on incremental treatments and give more runway to scale commercial investments sustainably.
Multi-year HCA Agreement ($40M)A committed multi-year refresh with a large hospital network provides structural revenue visibility and distribution scale. It anchors console placements, drives predictable consumables demand, and strengthens Outset's commercial positioning and credibility with other health systems.
Bears Say
Deep Unprofitability And Cash BurnPersistent heavy losses and negative free cash flow create ongoing funding and execution risk. Even with margin gains, continued negative cash conversion requires either sustained external financing or rapid margin and revenue improvement to avoid dilution or constrained growth options.
Dependence On Next-gen Tableau RampProjected back-half growth is materially tied to timing and market reception of the next-gen system. Any regulatory, production, or adoption delay would compress revenue realization and postpone expected consumables pull-through, undermining the currently forecasted path to improved cash flow.
Lumpy Capital Orders Reduce VisibilityHigh variability in capital equipment purchases makes installed-base growth and consumables forecasting less reliable. That volatility complicates operational planning and can delay the conversion of placements into steady recurring revenue, amplifying earnings and cash flow uncertainty.
Outset Medical News
OM FAQ
What was Outset Medical, Inc.’s price range in the past 12 months?
Outset Medical, Inc. lowest stock price was $3.00 and its highest was $21.36 in the past 12 months.
What is Outset Medical, Inc.’s market cap?
Outset Medical, Inc.’s market cap is $79.99M.
When is Outset Medical, Inc.’s upcoming earnings report date?
Outset Medical, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 35 days.
How were Outset Medical, Inc.’s earnings last quarter?
Outset Medical, Inc. released its earnings results on May 07, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.79 by -$0.04.
Is Outset Medical, Inc. overvalued?
According to Wall Street analysts Outset Medical, Inc.’s price is currently Undervalued.
Does Outset Medical, Inc. pay dividends?
Outset Medical, Inc. does not currently pay dividends.
What is Outset Medical, Inc.’s EPS estimate?
Outset Medical, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Outset Medical, Inc. have?
Outset Medical, Inc. has 18,537,241 shares outstanding.
What happened to Outset Medical, Inc.’s price movement after its last earnings report?
Outset Medical, Inc. reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.79. Following the earnings report the stock price went down -21.047%.
Which hedge fund is a major shareholder of Outset Medical, Inc.?
Currently, no hedge funds are holding shares in OM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outset Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.67 (76.25% Upside)
$7.67 (76.25% Upside)
Blogger Sentiment
Bullish
OM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.29%
12-Months-Change
Fundamentals
Return on Equity
-55.88%
Trailing 12-Months
Asset Growth
-17.18%
Trailing 12-Months
Company Description
Outset Medical, Inc.
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.
OM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial trajectory: substantial gross margin expansion (620 bps), a 32% improvement in non-GAAP net loss, strong cash balance ($161M) with lower-than-expected cash burn, and a strategic next-generation product and experienced commercial hire poised to drive future demand. Offsetting these positives were a 6% year-over-year revenue decline in Q1 driven by lumpiness in capital orders (product revenue down 13%), modestly higher operating expenses, and reliance on the timing and success of the next-gen Tableau launch to deliver back-half revenue. On balance, the positive margin, cash, and operational execution updates outweigh the timing-related revenue headwinds.View all OM earnings summariesOM Revenue Breakdown
47.04% Consoles
32.37% Consumables
20.59% Service and other revenue
OM Stock 12 Month Forecast
Average Price Target
$7.67
▲(76.25% Upside)
Technical Analysis
Ownership Overview
19.26% Insiders
21.41% Mutual Funds
24.03% Other Institutional Investors
28.68% Public Companies and
Individual Investors